Welcome to our dedicated page for YD Bio SEC filings (Ticker: YDESW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
YD Bio Limited’s SEC filings document foreign private issuer reports on material events, agreements, governance and regulatory-service activity. Form 6-K disclosures cover YD Bio USA’s strategic alliance agreement for FDA liaison and submission-support work, including IND, NDA and BLA-related projects, as well as capital-structure and clinical or regulatory disclosures.
The filings also record board committee appointments, audit committee composition, Nasdaq Listing Rule 5605 compliance, changes in certifying accountant and related audit disclosures, including going-concern language reported in prior audit reports. These records frame the company’s public disclosure around operating subsidiaries, governance controls, accounting oversight and regulatory-service partnerships.
YD Bio Ltd director Lu Shao-Ta reported equity compensation activity and updated share holdings. On June 30, 2026, he exercised 5,749 restricted share units (RSUs) into 5,749 ordinary shares at a stated price of $0.00 per share and received a new grant of 5,749 RSUs.
The RSUs relate to a March 31, 2026 award under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000, vesting in four equal quarterly installments based on a seven‑day volume‑weighted average price. Following these transactions, Lu holds 7,830 ordinary shares directly and 51,151 ordinary shares indirectly through his spouse.
YD Bio Ltd director Chang Kochi reported equity compensation activity involving Restricted Share Units (RSUs) and ordinary shares. On June 30, 2026, Kochi exercised 5,749 RSUs into the same number of ordinary shares at a stated price of $0.0000 per share, increasing direct holdings to 7,830 ordinary shares.
On the same date, Kochi also received a new grant of 5,749 RSUs with each RSU representing one ordinary share of YD Bio Ltd. According to the equity plan, the RSUs relate to a target aggregate grant date fair value of $60,000, vesting in four equal quarterly installments determined using a seven trading-day volume-weighted average price.
YD Bio Limited, a Cayman Islands company listed on the Nasdaq Global Market, files its annual report describing a young, loss-making healthcare business built around cancer blood tests and ophthalmology drugs. As of December 31, 2025, it had 70,789,261 ordinary shares and 15,142,911 warrants outstanding.
The report explains that YD Bio was created through a Business Combination with Breeze Holdings Acquisition Corp. and now owns all shares of YD Biopharma. Management discloses recurring losses, significant negative cash flow and substantial doubt about the company’s ability to continue as a going concern without new financing.
Key risks include dependence on critical IP licenses from EG BioMed and 3D Global, reliance on third‑party manufacturers, heavy revenue concentration in three major customers accounting for about 53.7% of 2025 revenue, and limited public‑company experience in the management team.
The company highlights extensive regulatory and reimbursement uncertainty: its cancer tests are Laboratory Developed Tests, future FDA oversight could change, and commercialization would require complex U.S. and foreign approvals and clinical trials. YD Bio is also exposed to Taiwan‑specific geopolitical and natural disaster risks, intellectual property disputes, potential PFIC and U.S. tax issues, and Nasdaq listing and dilution risks from public and private warrants.
YD Bio Ltd director Lu Shao-Ta updated his initial ownership report through an amended Form 3. The amendment adds disclosure of 51,151 Ordinary Shares held indirectly through his spouse that were previously omitted from his original Form 3 and one subsequent Form 4. This change reflects a correction in reported holdings, not a new share transaction.
YD Bio Ltd director Lu Shao-Ta reported equity compensation activity involving restricted share units (RSUs) that settled into ordinary shares. On March 31, 2026, he received 2,081 RSUs for no cash cost, each representing a right to one ordinary share. The same day, these RSUs were exercised and converted into 2,081 ordinary shares at a conversion price of $0.00 per share, leaving him with 2,081 ordinary shares from this grant and no remaining RSUs from this tranche. The award is part of a broader $60,000 RSU grant under YD Bio’s equity incentive plan, scheduled to vest in four equal quarterly installments based on the stock’s seven‑day volume‑weighted average price before each vesting date.
YD Bio Ltd director Chang Kochi reported equity compensation activity involving restricted share units. On March 31, 2026, Kochi received 2,081 restricted share units, each representing a right to one ordinary share.
The same day, 2,081 RSUs were exercised and converted into 2,081 ordinary shares at a price of $0.0000 per share, leaving 2,081 ordinary shares held directly after the transactions. The award was granted under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000, vesting in four equal quarterly installments of $15,000 each based on a seven trading-day volume-weighted average price.
YD Bio Ltd director Lu Shao-Ta has filed an initial Form 3 insider ownership report for YD Bio Ltd. The filing lists no reportable transactions or holdings, indicating this is an initial regulatory disclosure of insider status rather than a record of recent trading activity.
YD Bio Ltd director Chang Kochi filed an initial Form 3 reporting status as an insider of YD Bio Ltd (ticker YDES). The filing lists Kochi as a director and not a ten percent owner. No share transactions or derivative holdings are reported in this disclosure.
YD Bio Ltd director Lee Jerry Yin-Chia has filed a Form 3 insider report for YDES. The filing lists him as a director and indicates no reported purchases, sales, or other insider transactions, with all transaction counts and share totals recorded as zero.
YD Bio Ltd executive Hen Man Edmund, the Chief Financial Officer, filed an initial ownership report on Form 3. This filing establishes his status as an insider of the company but does not report any purchases, sales, or other equity transactions.